Ferlay J, Colombet M, Soerjomataram I et al (2021) Cancer statistics for the year 2020: an overview. Int J Cancer. https://doi.org/10.1002/ijc.33588

Article  PubMed  Google Scholar 

Hori M, Matsuda T, Shibata A et al (2015) Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol 45:884–891

Article  PubMed  Google Scholar 

Vis AN, Roemeling S, Reedijk AM et al (2008) Overall survival in the intervention arm of a randomized controlled screening trial for prostate cancer compared with a clinically diagnosed cohort. Eur Urol 53:91–98

Article  PubMed  Google Scholar 

Sevilla C, Maliski SL, Kwan L et al (2012) Long-term quality of life in disadvantaged men with prostate cancer on androgen-deprivation therapy. Prostate Cancer Prostatic Dis 15:237–243

Article  CAS  PubMed  Google Scholar 

Hoffman KE, Penson DF, Zhao Z et al (2020) Patient-reported outcomes through 5 years for active surveillance, surgery, brachytherapy, or external beam radiation with or without androgen deprivation therapy for localized prostate cancer. JAMA 323:149–163

Article  PubMed  PubMed Central  Google Scholar 

Chodak GW, Thisted RA, Gerber GS et al (1994) Results of conservative management of clinically localized prostate cancer. N Engl J Med 330:242–248

Article  CAS  PubMed  Google Scholar 

Johansson JE, Adami HO, Andersson SO et al (1992) High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA 267:2191–2196

Article  CAS  PubMed  Google Scholar 

Tosoian JJ, Mamawala M, Epstein JI et al (2015) Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer. J Clin Oncol 33:3379–3385

Article  PubMed  PubMed Central  Google Scholar 

Klotz L, Vesprini D, Sethukavalan P et al (2015) Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 33:272–277

Article  PubMed  Google Scholar 

Godtman RA, Holmberg E, Khatami A et al (2016) Long-term results of active surveillance in the goteborg randomized, population-based prostate cancer screening trial. Eur Urol 70:760–766

Article  PubMed  Google Scholar 

Welty CJ, Cowan JE, Nguyen H et al (2015) Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer. J Urol 193:807–811

Article  PubMed  Google Scholar 

Selvadurai ED, Singhera M, Thomas K et al (2013) Medium-term outcomes of active surveillance for localised prostate cancer. Eur Urol 64:981–987

Article  PubMed  Google Scholar 

Bokhorst LP, Valdagni R, Rannikko A et al (2016) A decade of active surveillance in the prias study: an update and evaluation of the criteria used to recommend a switch to active treatment. Eur Urol 70:954–960

Article  PubMed  Google Scholar 

Cooperberg MR, Broering JM, Litwin MS et al (2004) The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol 171:1393–1401

Article  PubMed  Google Scholar 

Cancer Registration Committee of the Japanese Urological A (2005) Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int J Urol 12:46–61

Article  Google Scholar 

Kakehi Y, Kamoto T, Shiraishi T et al (2008) Prospective evaluation of selection criteria for active surveillance in Japanese patients with stage T1cN0M0 prostate cancer. Jpn J Clin Oncol 38:122–128

Article  PubMed  Google Scholar 

Urology EAo (2023) Oncology guidelines “prostate cancer”.

Network NCC (2023) NCCN clinical practice guidelines in oncology: prostate cancer, version 4.2023.

Kakehi Y, Sugimoto M, Taoka R et al (2017) Evidenced-based clinical practice guideline for prostate cancer (summary: Japanese Urological Association, 2016 edition). Int J Urol. 24:648–666

Article  PubMed  Google Scholar 

Omri N, Kamil M, Alexander K et al (2020) Association between PSA density and pathologically significant prostate cancer: the impact of prostate volume. Prostate 80:1444–1449

Article  CAS  PubMed  Google Scholar 

Campbell SR, Tom MC, Agrawal S et al (2022) Integrating prostate-specific antigen kinetics into contemporary predictive nomograms of salvage radiotherapy after radical prostatectomy. Eur Urol Oncol 5:304–313

Article  PubMed  Google Scholar 

Simpkin AJ, Tilling K, Martin RM et al (2015) Systematic review and meta-analysis of factors determining change to radical treatment in active surveillance for localized prostate cancer. Eur Urol 67:993–1005

Article  PubMed  Google Scholar 

Dai C, Ganesan V, Zabell J et al (2018) Impact of 5alpha-reductase inhibitors on disease reclassification among men on active surveillance for localized prostate cancer with favorable features. J Urol 199:445–452

Article  CAS  PubMed  Google Scholar 

Sugimoto M, Kakehi Y, Horie S et al (2022) A randomized controlled trial evaluating the effect of low-dose chlormadinone in patients with low-risk prostate cancer: PROSAS study. Jpn J Clin Oncol 52:187–196

Article  PubMed  Google Scholar 

Sugimoto M, Hirama H, Yamaguchi A et al (2015) Should inclusion criteria for active surveillance for low-risk prostate cancer be more stringent? From an interim analysis of PRIAS-JAPAN. World J Urol 33:981–987

Article  PubMed  Google Scholar 

Bokhorst LP, Lepisto I, Kakehi Y et al (2016) Complications after prostate biopsies in men on active surveillance and its effects on receiving further biopsies in the Prostate cancer Research International: Active Surveillance (PRIAS) study. BJU Int 118:366–371

Article  CAS  PubMed  Google Scholar 

D’Amico AV, Whittington R, Malkowicz SB et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969–974

Article  CAS  PubMed  Google Scholar 

Loeb S, Folkvaljon Y, Bratt O et al (2019) Defining intermediate risk prostate cancer suitable for active surveillance. J Urol 201:292–299

Article  PubMed  Google Scholar 

Epstein JI, Allsbrook WC Jr, Amin MB et al (2005) The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 29:1228–1242

Article  PubMed  Google Scholar 

Samaratunga H, Delahunt B, Gianduzzo T et al (2015) The prognostic significance of the 2014 International Society of Urological Pathology (ISUP) grading system for prostate cancer. Pathology 47:515–519

Article  PubMed  Google Scholar